Abstract:OBJECTIVE:To detect the levels of serum C-C chemokine ligand 19 (CCL19) in patients with systemic lupus erythematosus (SLE) and to evaluate the correlation between CCL19 expression and clinical features and laboratory parameters, trying to reveal the possible role of CCL19 in the pathogenesis of systemic lupus erythematosus.METHODS:The levels of serum CCL19 were measured by enzyme linked immunosorbent assay (ELISA) in 90 patients with SLE and 30 healthy controls. These SLE patients included 75 patients who received treatment with glucocorticoids and disease-modifying anti-rheumatic drug (DMARD) and 15 patients without therapy. The frequencies of peripheral blood B cells and the B cell subsets were assessed in the patients with SLE by flow cytometry. The correlation between the clinical data, laboratory parameters, B cell subset frequencies and serum CCL19 levels were analyzed. Indepen-dent samples t test, paired t test, Pearson and Spearman correlation were used for statistical analyses.RESULTS:The levels of CCL19 were markedly higher in the SLE patients without therapy and the patients with therapy than in the health controls[(596.25±409.19) ng/L and (422.90±395.84) ng/L vs. (157.79±125.23) ng/L, all P<0.001]. Serum CCL19 levels in the SLE patients without therapy were higher than the SLE patients who accepted glucocorticoids and DMARD treatment (P<0.05). The levels of serum CCL19 were positively correlated with anti-double stranded deoxyribonucleic acid (dsDNA), anti-nucleosome antibody (AnuA), IgA, IgG and IgM (r=0.38, P=0.007; r=0.332, P=0.029; r=0.519, P=0.007; r=0.461, P=0.018, respectively). Serum CCL19 levels in the SLE patients with photosensitivity, arthritis and secondary Sjögren's syndrome were higher than the SLE patients without photosensitivity, arthritis and secondary Sjögren's syndrome, respectively [(562.25±399.12) ng/L, (565.6±435.24) ng/L and (694.9±531.02) ng/L vs. (394.7±281.42) ng/L, (385.90±325.33) ng/L and (424.8±305.46) ng/L, all P<0.05]. The levels of serum CCL19 were positively correlated with the percentage of CD27-B cells and CD27-IgD-double-negative memory B cells (r=0.519, P=0.007; r=0.461, P=0.018, respectively). However, the levels of serum CCL19 were negatively correlated with the percentage of CD27+ memory B cells and CD27+IgD- switched memory B cells (r=-0.433, P=0.027; r=-0.616, P=0.001, respectively).CONCLUSION:The increased serum CCL19 levels in SLE patients were associated with the production of autoantibodies, and CCL19 might be involved in the pathogenesis of SLE by disturbing the homeostasis of B cell subsets.

Different expression patterns and clinical significance of mAxl and sAxl in systemic lupus erythematosus.

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

The Clinical Significance of Soluble Axl and Tyro3 Receptor Tyrosine Kinase in Systemic Lupus Erythematosus

Aberrant CD200/CD200R1 Expression and Function in Systemic Lupus Erythematosus Contributes to Abnormal T-cell Responsiveness and Dendritic Cell Activity

Abnormal Expression of Cd43 in Patients with Systemic Lupus Erythematosus and Its Clinical Significance

lncRNA X-inactive-specific transcript is a potential biomarker related to changes in CD4 + T cell levels in systemic lupus erythematosus

[Clinical Significance of CD4+CD25+ T Cells in Peripheral Blood of Patients in Systemic Lupus Erythematosus].

LncRNA XIST Alters the Balance of Peripheral Blood Immune Cells in Systemic Lupus Erythematosus by Regulating the miR-17-92/OFLM4 and CEACAM8 Axis

Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with systemic lupus erythematosus and Behçets disease

Expressions of BAFF/BAFF Receptors and Their Correlation with Disease Activity in Chinese SLE Patients

IL-10 and IFN-γ As Markers for Early Recognition of Pediatric Systemic Lupus Erythematosus Complicated with Macrophage Activation Syndrome.

Bulk and Single-Cell Transcriptome Analysis Reveal Shared Key Genes and Patterns of Immune Dysregulation in Sepsis and Systemic Lupus Erythematosus

The Expression and Clinical Significance of Different Forms of Mer Receptor Tyrosine Kinase in Systemic Lupus Erythematosus.

Upregulation of CX3CR1 expression in circulating T cells of systemic lupus erythematosus patients as a reflection of autoimmune status through characterization of cytotoxic capacity

Detection of plasma protein S and growth-arrest specific protein 6 and their clinical significance in systemic lupus erythematosus

The aberrant expression of CD45 isoforms and levels of sex hormones in systemic lupus erythematosus

Serum levels of CXCL5 are decreased and correlate with circulating platelet counts in systemic lupus erythematosus

Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus

The CXCL13 chemokine serves as a potential biomarker to diagnose systemic lupus erythematosus with disease activity

[Increased Serum C-C Chemokine Ligand 19 Levels Correlated with B Cell Abnormalities in Systemic Lupus Erythematosus].